To conduct a comprehensive investigation of tendon disorders associated with third-generation aromatase inhibitors using data from the FDA’s FAERS database.
Approach:
Data Retrieval: Reports of tendon disorders related to third-generation aromatase inhibitors were retrieved from the FAERS database from Q1 2004 to Q1 2024.
Data Analysis: The data were analyzed using proportional analysis and a Bayesian approach to detect signals of tendon disorders induced by the three drugs.
Clinical Characteristics Examination: Clinical characteristics, onset time, correlation, and stratification analysis of tendon disorders associated with the three drugs were examined.
Key Findings:
Twelve positive signals for tendon disorders associated with third-generation aromatase inhibitors were identified, including significant signals for trigger finger and tenosynovitis stenosans.
Letrozole exhibited the earliest onset of tendon disorders at 74 days, while exemestane showed the latest at 243.5 days.
A clear association between third-generation aromatase inhibitors and tendon disorders was observed after excluding the effect of combination drugs.
Interpretation:
Analysis of the FAERS database has identified risk trends for tendon disorders associated with third-generation aromatase inhibitors, revealing varying degrees of tendon toxicity and distinct time-to-onset profiles.
Conclusion:
The study provides insights into tendon disorders associated with third-generation aromatase inhibitors.
